In the current study, we found that decreased FAM117A expression in lung cancer cells warrants cell cycle progression by releasing the G1/S checkpoint, which could be fully rescued by CDK4/6 inhibitors and provides a molecular basis for treatment of lung cancer patients with CDK inhibitors or other cell cycle modulators. Here, FAM117A is linked to lung cancer.